drugset / Trial / NCT02018757
Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
Phase 2
Unknown
250 enrolled
First Hospital of China Medical University
Fudan University · collabSun Yat-sen University · collabXijing Hospital · collabZhongda Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to determine whether transarterial chemoembolization containing arsenic trioxide is safe and effective in the treatment of intermediate-stage hepatocellular carcinoma.
Timeline
- Start
- 2014-01
- Primary completion
- 2015-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | arsenic trioxide | Small molecule | 20 mg | Other |
| Comparator | Doxorubicin | Other / unclassified | 40 mg | Other |